作者: Beibei Sun , Wenzheng Guo , Song Hu , Feng Yao , Keke Yu
DOI: 10.18632/ONCOTARGET.14589
关键词:
摘要: // Beibei Sun 1, * , Wenzheng Guo 2, 3, Song Hu 1 Feng Yao 4 Keke Yu 5 Jie Xing Ronghua Wang Hongyong 3 Yueling Liao Tong Pengfei Jiang 6 Baohui Han 7 Jiong Deng Translation Medicine Center, Shanghai Chest Hospital, Jiao University, Shanghai, China 2 Key Laboratory of Cell Differentiation and Apoptosis Chinese Minister Education, Department Pathophysiology, University School Medicine, for Tumor Microenvironment Inflammation, Thoracic Surgery, Biobank, East Tongji Pulmonary These authors contributed equally to this work Correspondence to: Han, email: xkyyhan@gmail.com Deng, jiongdeng@shsmu.edu.cn Keywords: lung cancer, biomarker, ceruloplasmin, Gprc5a Received: November 15, 2016 Accepted: December 31, Published: January 10, 2017 ABSTRACT Lung cancer is the leading cause death. As most patients were diagnosed with advanced stage, early detection considered as effective strategy reduce high mortality. Thus, it desirable identify specific biomarkers at stages tumorigenesis. GPRC5A a tumor suppressor gene. deficiency linked development. We hyposthesized that, dysregulated gene expression that results from may provide potential By analysis top 20 upregulated genes in mouse tracheal epithelial cells (MTEC) knockout (KO) vs wild-type (WT), we found lipocalin-2, periostin are not only Gprc5a-ko mice, but also expressed levels tissues mice. This suggests increased these associated Importantly, has been be significantly increased, both mRNA protein levels, NSCLC patients, which correlated repressed GPRC5A. used